Drug resistance caused by oncogene mutations or activation of oncogenic signaling pathways and increased tumor plasticity is the major obstacle encountered in the application of target therapies such as anti-EGFR therapy [91,127]. The gene discussed is EGFR; the disease is neoplasm.